Showing 2921-2930 of 5646 results for "".
- Alcon Introduces Preloaded Delivery System for the CyPass Micro-Stenthttps://modernod.com/news/alcon-introduces-preloaded-delivery-system-for-the-cypass-micro-stent/2480245/Alcon has announced the launch of the CyPass Ultra System designed to streamline the process of loading the CyPass Micro-Stent, a microinvasive glaucoma surgery (MIGS) device indicated for use in adult patients with mild-to-moderate primary open-angle glaucoma undergoing cataract surgery. The new
- Allergan Announces Official Launch of the TrueTear Intranasal Neurostimulation Devicehttps://modernod.com/news/allergan-announces-launch-of-the-truetear-intranasal-neurostimulation-device-at-ascrs/2480250/Allergan announced the official launch of TrueTear, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients. TrueTear, a handheld neurostimulation device with disposable tips that is inserted into the nasal cavity to
- FDA Approves Marketing For First AI Device for Diabetic Retinopathy Detectionhttps://modernod.com/news/fda-permits-marketing-of-ai-based-device-to-detect-certain-diabetes-related-eye-problems/2480256/The FDA has permitted marketing for the first medical device to use artificial intelligence to detect greater than a mild level of diabetic retinopathy in adults who have diabetes. The device, called IDx-DR, is a software program that uses an artificial intelligence algorithm to analyze im
- Veteran Business Development Executive Joins Lions Eye Institute as CMOhttps://modernod.com/news/veteran-business-development-executive-joins-lions-eye-institute-as-cmo/2480260/The Lions Eye Institute for Transplant & Research has announced the hiring of its first Chief Marketing Officer, Art Kurz, to strengthen the organization’s business development activities. Mr. Kurz, a former U.S. Air Force medic and graduate of Towson University, comes to Lions Eye Ins
- China Approves World’s First Implantable Device for Congenital Nystagmus Treatmenthttps://modernod.com/news/china-approves-worlds-first-implantable-device-for-congenital-nystagmus-treatment/2486098/
- International Study Shows Large Language Models Now Excel on Ophthalmology Specialty Exams but Risks Remainhttps://modernod.com/news/international-study-shows-large-language-models-now-excel-on-ophthalmology-specialty-exams-but-risks-remain/2485591/A new study published this week in Eye reveals that the latest generation of large language models (LLMs) have made dramatic gains in performance on specialty o
- New Study Shows Foundation AI Models Closing the Gap With Doctors—But Multimodal Challenges Remainhttps://modernod.com/news/new-study-shows-foundation-ai-models-closing-the-gap-with-doctorsbut-multimodal-challenges-remain/2485340/A new cross-sectional study published in JAMA Ophthalmology examines how current foundation artificial intelligence (AI) models perform on ophthalmology exam questions compared with human physicians. The data reveal notable progress on text-based tasks but
- Everest Medicines Expands into Ophthalmology with Licensing Agreement for Retinal Disease Candidate in Asiahttps://modernod.com/news/everest-medicines-expands-into-ophthalmology-with-licensing-agreement-for-retinal-disease-candidate-in-asia/2484302/Everest Medicines announced it has entered into an exclusive licensing agreement with Visara, a subsidiary of NovaBridge Biosciences to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and select Southeast Asian countri
- Oculis Prices $110 Million Financing to Accelerate Privosegtor Developmenthttps://modernod.com/news/oculis-prices-110-million-financing-to-accelerate-privosegtor-development/2484298/Oculis announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares at a price of $20.25 per share for total gross proceeds of $110 million. The net proceeds from the financing will be used to advance and accelerate the d
- Regeneron Delays Regulatory Submission for Eylea HD Pre-Filled Syringe After CRLhttps://modernod.com/news/regeneron-delays-regulatory-submission-for-eylea-hd-pre-filled-syringe-after-crl/2484294/In its third quarters earnings filing, Regeneron said it received another complete response letter (CRL) from the FDA for its pre-filled syringe supplemental BLA (sBLA) for Eylea HD (aflibercept injection 8 mg). The sole approvability issue cited in the CRL relates to unresolved inspection findin